23andMe, the genetics startup that has again and again captured the general public creativeness after which confronted just about deadly industry demanding situations, introduced Monday that it will halt its efforts to expand new medications and lay off 40% of its staff, focusing as an alternative on promoting genetic checks to shoppers and the usage of the ensuing knowledge for analysis.
In final its therapeutics department and shedding 200 other people, 23andMe ended an audacious wager it made just about a decade in the past — that it would use the genetic knowledge it had gathered now not simplest to lend a hand drug firms however to turn into one itself.
“We’re taking those tricky however vital movements as we restructure 23andMe and concentrate on the long-term luck of our core shopper industry and analysis partnerships,” stated Anne Wojcicki, 23andMe’s CEO, co-founder, and chair of the board. “I wish to thank our staff for his or her onerous paintings and determination to our undertaking. We’re absolutely dedicated to supporting the workers impacted by means of this transition.”
STAT+ Unique Tale
Have already got an account? Log in
This text is unique to STAT+ subscribers
Liberate this newsletter — plus day by day protection and research of the biotech sector — by means of subscribing to STAT+.
Have already got an account? Log in
Person plans
Workforce plans
View All Plans
To learn the remainder of this tale subscribe to STAT+.
Subscribe
/cdn.vox-cdn.com/uploads/chorus_asset/file/25730994/526258524.jpg "Can the United States triple its nuclear power capability?")
